✓ Translated by DotMD AI Clinical Council Source: International journal of cardiology • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #19118910 ↗

Randomized Controlled Trial: Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance (N = 24)

Original Paper Title: “Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 24
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • In hypertensive patients with IGT telmisartan compared to losartan improved endothelial function and insulin resistance independently, supporting the hypothesis that glucometabolic and vascular insulin resistance are differentially regulated.
  • Study Design & Sample: Randomized Controlled Trial published in International journal of cardiology (N = 24 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in International journal of cardiology (2010), this randomized controlled trial evaluating 24 human participants investigated: Hypertensive patients with IGT have increased risk for cardiovascular disease and progression to diabetes mellitus. Key clinical takeaway: In hypertensive patients with IGT telmisartan compared to losartan improved endothelial function and insulin resistance independently, supporting the hypothesis that glucometabolic and vascular insulin resistance are differentially regulated.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (International journal of cardiology, 2010-03-18; N = 24; Rigor 88/100): In hypertensive patients with IGT telmisartan compared to losartan improved endothelial function and insulin resistance independently, supporting the hypothesis that glucometabolic and vascular insulin resistance are differentially regulated.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: telmisartan → Rx: glucose-and-sodium-chloride-dextrose-anhydrous-and-sodium-chloride → Condition: renal-vein-thrombosis → Condition: embolism-septic →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 19118910: Randomized Controlled Trial: Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance (N = 24)

3 of 3 Free Questions Remaining